TFS Chemicals - Aspire
Pharma Focus America
Sino Biological - Cytokine

Launch of Initial Product Leveraging LTS Sorrel™ Wearable Drug Delivery Platform in the US

Thursday, February 29, 2024

Today, LTS LOHMANN Therapie-Systeme AG ("LTS"), a prominent pharmaceutical technology company, declared the launch of the UDENYCA® on-body injector (OBI) by its client, Coherus BioSciences, Inc ("Coherus"), utilizing the LTS Sorrel™ wearable drug delivery platform. UDENYCA® (pegfilgrastim-cbqv) is a biosimilar pegfilgrastim given the day after chemotherapy to reduce the risk of infection, specifically febrile neutropenia. The UDENYCA® OBI obtained approval from the U.S. Food and Drug Administration (FDA) in December 2024. This device sets new standards for performance, quality, reliability, and patient convenience in wearable injection devices.

Coherus and LTS have collaborated to obtain approval for the delivery of UDENYCA® OBI. This novel drug delivery device platform aims to provide UDENYCA® patients with the drug in the comfort of their homes, reducing their infection risk post-chemotherapy.

LTS, stated: "This launch marks LTS's entry into Biologics, extending the ease of administration that LTS solutions are renowned for to a new class of therapies. Our capacity is poised to scale up, ensuring swift access to this beneficial solution for all patients."

"The FDA's approval was a resounding vote of confidence and a significant milestone for the Sorrel™ platform. The launch demonstrates our ability to manufacture and deliver according to market demands," commented Dr. Andrei Yosef, President and General Manager of LTS Device Technologies. "This approval and launch will expedite our other partnered programs running on the same platform, as well as programs with partners seeking market access in the future."

Sorrel™ technology offers pre-filled, pre-loaded, and pre-assembled wearable drug delivery devices, facilitating easy-to-use at-home administration. Ranging from 1mL to 50 mL, the Sorrel™ platform is agnostic to primary containers, enabling seamless integration into pharmaceutical company products.

 

Source: prnewswire.com

patheon - Mastering API production at every scaleWorld Vaccine Congress Europe 2024World Orphan Drug Congress 2024Future Labs Live USA 2024patheon - Revolutionizing PharmaHealthcare CNO SummitHealthcare CMO Summit